FINWIRES · TerminalLIVE
FINWIRES

Morgan Stanley Upgrades Arrowhead Pharmaceuticals to Overweight From Equal Weight, Adjusts PT to $100 From $78

-- Arrowhead Pharmaceuticals (ARWR) has an average rating of Buy and mean price target of $84.80, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

相关文章